123 related articles for article (PubMed ID: 11680017)
1. [The value of positron emission tomography (PET) in the treatment of patients with cancer of unknown primary (CUP)].
Rades D; Kühnel G; Wildfang I; Börner AR; Knapp W; Karstens JH
Strahlenther Onkol; 2001 Oct; 177(10):525-9. PubMed ID: 11680017
[TBL] [Abstract][Full Text] [Related]
2. Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management.
Rades D; Kühnel G; Wildfang I; Börner AR; Schmoll HJ; Knapp W
Ann Oncol; 2001 Nov; 12(11):1605-9. PubMed ID: 11822762
[TBL] [Abstract][Full Text] [Related]
3. Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry.
Subramaniam RM; Shields AF; Sachedina A; Hanna L; Duan F; Siegel BA; Hillner BE
Oncologist; 2016 Sep; 21(9):1079-84. PubMed ID: 27401896
[TBL] [Abstract][Full Text] [Related]
4. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.
Pelosi E; Pennone M; Deandreis D; Douroukas A; Mancini M; Bisi G
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200
[TBL] [Abstract][Full Text] [Related]
5. PET with 2-[F-18]-fluoro-2-deoxy-D-glucose (FDG) in patients with cancer of unknown primary (CUP): influence on patients' diagnostic and therapeutic management.
Mantaka P; Baum RP; Hertel A; Adams S; Niessen A; Sengupta S; Hör G
Cancer Biother Radiopharm; 2003 Feb; 18(1):47-58. PubMed ID: 12667308
[TBL] [Abstract][Full Text] [Related]
6. 2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation.
Jungehülsing M; Scheidhauer K; Damm M; Pietrzyk U; Eckel H; Schicha H; Stennert E
Otolaryngol Head Neck Surg; 2000 Sep; 123(3):294-301. PubMed ID: 10964310
[TBL] [Abstract][Full Text] [Related]
7. Value of fused positron emission tomography CT in detecting primaries in patients with primary unknown cervical lymph node metastasis.
Chen YH; Yang XM; Li SS; Wang YH; He JJ; Yang YD; Wang S; Liu JJ; Zhang XL
J Med Imaging Radiat Oncol; 2012 Feb; 56(1):66-74. PubMed ID: 22339748
[TBL] [Abstract][Full Text] [Related]
8. ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography as an effective diagnostic workup in cervical metastasis of carcinoma from an unknown primary tumor.
Zhao K; Luo XM; Zhou SH; Liu JH; Yan SX; Lu ZJ; Yang SY; Lin LL; Dong MJ
Cancer Biother Radiopharm; 2012 Dec; 27(10):685-93. PubMed ID: 22834634
[TBL] [Abstract][Full Text] [Related]
9. The value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of an unknown primary: diagnosis and follow-up.
Yapar Z; Kibar M; Yapar AF; Paydas S; Reyhan M; Kara O; Buyukdereli G; Aydin M; Kelle AP; Unal I; Disel U; Yavuz S; Sahin B; Erkisi M
Nucl Med Commun; 2010 Jan; 31(1):59-66. PubMed ID: 19952921
[TBL] [Abstract][Full Text] [Related]
10. Prediction of survival and evaluation of diagnostic accuracy whole body 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the detection carcinoma of unknown primary origin.
Tamam MO; Mulazimoglu M; Guveli TK; Tamam C; Eker O; Ozpacaci T
Eur Rev Med Pharmacol Sci; 2012 Dec; 16(15):2120-30. PubMed ID: 23280029
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study.
Johansen J; Buus S; Loft A; Keiding S; Overgaard M; Hansen HS; Grau C; Bundgaard T; Kirkegaard J; Overgaard J
Head Neck; 2008 Apr; 30(4):471-8. PubMed ID: 18023031
[TBL] [Abstract][Full Text] [Related]
12. Detection of occult primary tumors in patients with cervical metastases of unknown primary tumors: comparison of (18)F FDG PET/CT with contrast-enhanced CT or CT/MR imaging-prospective study.
Lee JR; Kim JS; Roh JL; Lee JH; Baek JH; Cho KJ; Choi SH; Nam SY; Kim SY
Radiology; 2015 Mar; 274(3):764-71. PubMed ID: 25405771
[TBL] [Abstract][Full Text] [Related]
13. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities.
Regelink G; Brouwer J; de Bree R; Pruim J; van der Laan BF; Vaalburg W; Hoekstra OS; Comans EF; Vissink A; Leemans CR; Roodenburg JL
Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1024-30. PubMed ID: 12173016
[TBL] [Abstract][Full Text] [Related]
14. Management of the unknown primary carcinoma: long-term follow-up on a negative PET scan and negative panendoscopy.
Miller FR; Karnad AB; Eng T; Hussey DH; Stan McGuff H; Otto RA
Head Neck; 2008 Jan; 30(1):28-34. PubMed ID: 17657782
[TBL] [Abstract][Full Text] [Related]
15. FDG-PET/CT for detection of the unknown primary head and neck tumor.
Johansen J; Petersen H; Godballe C; Loft A; Grau C
Q J Nucl Med Mol Imaging; 2011 Oct; 55(5):500-8. PubMed ID: 22019707
[TBL] [Abstract][Full Text] [Related]
16. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
Wu ZJ; Zhang YX; Wei H; Jia Q
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
[TBL] [Abstract][Full Text] [Related]
17. The usefulness of fluorine 18-labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor.
Fogarty GB; Peters LJ; Stewart J; Scott C; Rischin D; Hicks RJ
Head Neck; 2003 Feb; 25(2):138-45. PubMed ID: 12509797
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT).
Lassen U; Daugaard G; Eigtved A; Damgaard K; Friberg L
Eur J Cancer; 1999 Jul; 35(7):1076-82. PubMed ID: 10533451
[TBL] [Abstract][Full Text] [Related]
19. Whole-body positron emission tomography using fluorodeoxyglucose in patients with metastases of unknown primary tumours (CUP syndrome).
Alberini JL; Belhocine T; Hustinx R; Daenen F; Rigo P
Nucl Med Commun; 2003 Oct; 24(10):1081-6. PubMed ID: 14508164
[TBL] [Abstract][Full Text] [Related]
20. [Usefulness of (18)F-fluorodeoxyglucose-positron emission tomography-computerized tomography in the identification of the primary tumor in patients with cancer of unknown origin].
Talavera-Rubio Mdel P; García-Vicente AM; Palomar-Muñoz AM; Pilkington-Woll JP; Poblete-García VM; Soriano-Castrejón A
Med Clin (Barc); 2013 Jan; 140(1):14-9. PubMed ID: 23177314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
